Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO

Handelsbanken Fonder AB grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 631,899 shares of the biopharmaceutical company’s stock after acquiring an additional 138,430 shares during the quarter. Handelsbanken Fonder AB owned about 0.53% of Halozyme Therapeutics worth $49,459,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of HALO. Arrowstreet Capital Limited Partnership raised its holdings in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after buying an additional 25,731 shares during the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $128,201,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $124,031,000. Finally, Federated Hermes Inc. raised its holdings in Halozyme Therapeutics by 8.5% in the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after acquiring an additional 123,917 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 44,103 shares of company stock worth $3,142,896 over the last three months. 2.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on HALO. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. TD Cowen boosted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. HC Wainwright increased their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $102.62 on Wednesday. The business has a 50-day simple moving average of $77.89 and a two-hundred day simple moving average of $71.92. The company has a market cap of $11.65 billion, a P/E ratio of 30.63, a P/E/G ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $104.78. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter last year, the firm posted $1.54 earnings per share. The firm’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.